Good News | MiStent® Coronary Drug-Eluting Stent Approved, Offering a New Clinical Option for PCI!
Recently, MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System, the flagship product of Mixin Medtech, a subsidiary of Kossel Group, has been successfully approved for market launch by the National Medical Products Administration (NMPA) (Registration Certificate No.: GXZZ 20263130833). MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System was developed following Kossel Group’s complete acquisition of […]
Kossel Debuts at CCT 2025, Deepening Penetration in the Asian Market
From October 23 to 24, 2025, the 2025 Complex Cardiovascular Therapeutics (CCT 2025) was grandly held in Kobe, Japan. As one of the most influential academic conferences on cardiovascular interventional therapy in Asia, it shares the latest advancements in PCI therapy, structural heart disease, and surgical treatment through live surgical demonstrations, special seminars, and academic […]
SOLACI SOCIME 2025 | Unlock the Latin American Medical Market and Jointly Build a Global Health Future!
The 2025 Annual Congress of the Latin American Society of Interventional Cardiology (SOLACI SOCIME 2025) was grandly held in Mexico from August 6 to 8. As the most influential cardiovascular intervention event in Latin America, SOLACI brought together experts and scholars in the field of cardiovascular intervention from various countries in Latin America and around […]